



ORIGINAL RESEARCH ARTICLE

OPEN ACCESS

ARGINASE-1, FIBRONECTIN, IL-13, TISSUE INHIBITOR OF METALLOPROTEINASE-1 AS INDICATOR HEPATOCELLULAR CARCINOMA ON SPRAGUE-DAWLEYRATS INDUCED BY DIETHYLNITROSAMINE AND N-MORPHOLINE

*Siti Muchayat Purnamaningsih

Departement of Clinical Pathology and Laboratory Medicine , Faculty of Medicine,
GadjahMada University, Yogyakarta, Indonesia

ARTICLE INFO

Article History:

Received 19th August 2017
Received in revised form
22nd September, 2017
Accepted 23rd October, 2017
Published online 29th November, 2017

Key Words:

Arginase-1,
Fibronectin,
IL-13, TIMP-1,
Histopathology HCC.

ABSTRACT

Background: Hepatocellular carcinoma (HCC) characterized by stromal fibrosis develops in 90% of cases of liver cirrhosis, during the clinical course of chronic liver inflammation. Arginase-1 (Arg-1), fibronectin (FN), IL-13, and the inhibitor of metalloproteinase-1 (TIMP-1) are important regulators of proliferation, differentiation, tumorigenesis. This study was conducted to investigate the progression of liver fibrosis (cirrhosis) to HCC by inducing diethyl-nitrosamine (DEN) and N-nitrosomorpholine (N-Mor) in Sprague-Dawleyrats.

Methods: This study was the experimental design with randomized groups. A total of forty *Sprague-Dawley* (SD) rats, male, were divided into a control group of ten SD rats, and the treatment group was induced resulting in fibrosis of the liver, and HCC. Statistical analysis was performed by multiregression analysis and Mann Whitney test.

Results: This study showed Arg-1, FN, IL-13 and TIMP-1 have strongly and significantly correlate with stromal fibrosis by histopathology ($r = -0.870$, $r = -0.791$, $r = 0.932$, $r = 0.808$, $p = 0.000$ respectively). We found that there are significantly difference level of Arg-1 and FN ($p=0.041$; $p 0.002$, respectively) between cirrhosis and hepatocellular carcinoma, meanwhile markers of IL-13, TIMP-1 was not significant.

Conclusions: The serology marker of Arg-1 or FN could be used as the indicator of HCC.

*Corresponding author

Copyright ©2017, Siti Muchayat Purnamaningsih. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Siti Muchayat Purnamaningsih. 2017. "Arginase-1, Fibronectin, IL-13, Tissue Inhibitor of Metalloproteinase-1 as Indicator Hepatocellular Carcinoma on Sprague-DawleyRats Induced by Diethylnitrosamine and N-Morpholine.", *International Journal of Development Research*, 7, (11), 16745-16749.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death, which initiated by the clinical course of chronic liver diseases that cause fibrosis of the liver (Mittal, 2013). In HCC, DNA ploidy, proliferating activity of tumor cells, tumor suppressor and promotor genes, cells cycle controllers, proteinases that degrade extracellular matrix, adhesion molecules, angiogenic factors, metabolic genes, have been regarded as biomarkers for the malignant phenotype of HCC, and related to progression (Lin-Xiu, 2002). During tumour progression the malignant hepatocytes and activated hepatic stellate cells are accompanied by cancer-associated fibroblasts, myofibroblasts and immune cells generally called

tumour stromal cells (El Fatah *et al.*, 2016). The genomic point of view on alterations of cellular microenvironment in liver cancers, particularly the stromal tissue, emphasizing the importance of the crosstalk between tumor cells and stromal cells, notably activated hepatic stellate cells (HSC), in tumor onset and progression (Lin-Xiu, 2002). Difficulty in describing the process of stromal fibrosis progress to stromal cancer, with conventional clinical laboratory tests that general and specific, ultrasound, histopathology. Inconsistent criteria and measurement errors such methods, as well as different cut-off limits influential in the evaluation of progressivity HCC. Hepatocellular Carcinoma originates from chronic necroinflammation which is a key element of HCC occurrence

that can induce chromosomal mutations and eventually malignant transformation of proliferating hepatocytes (Lin-Xiu, 2002). Several facts support that the role of liver stellate cells (HSC) are interrelated with markers arginase-1 (Arg-1), cytokine IL-13, extracellular matrix fibronectin (FN), and Tissues Inhibitor of Metalloproteinase-1 (TIMP-1) in the pathogenesis of liver fibrosis and schirrous HCC (Wynn, 2004; Yan *et al.*, 2010). Direct seromarker of Arg-1, FN, IL-13, and TIMP-1 in this study focused as a marker in the follow-up of liver fibrosis (progression) to cirrhosis and HCC, especially the role ARG-1 at necroinflammation persistent, increased cytokine IL-13 activation of fibroblasts, deposition FN and the changing balance of fibrogenesis and fibrinolysis with increased TIMP-1 due to increased expression of mRNA and the gene of TIMP-1 (Lichtinghagen *et al.*, 2003; Feng *et al.*, 2009; Pinzani *et al.*, 2005). In this research, the material of carcinogen DEN and N-Mor came to the substance along with SD rats as a model that causes inflammation, destruction and fibrosis until the HCC (Lin-Xiu Qin, 2002; Chuang *et al.*, 2009). The aims of this research is to find out the model of serology marker circulating Arg-1, FN, IL-13, activities of TIMP-1 as the indicator of the progressivity in the growth of chronic hepatitis disease/fibrosis which developed into the cirrhosis and HCC.

This study is an analytical observational with randomized group experimental design, conducted from August to November 2014, located in Department of Clinical Pathology and Laboratory Medicine, Anatomical Pathology at Medical Faculty of GadjahMada University, Clinical Laboratory Installation of Prof. Dr. Sardjito General Hospital and Integrated Research of Testing Laboratories of GadjahMada University, Yogyakarta, Indonesia. The subject consist of 30 SD rats treatment and 10 SD rats control, divided in 6 SD treatment rats and 2 SD control rats in each treatment group (4th, 8th, 10th, 12th, and 14th week).

Hepatitis cirrhosis was made using the induction of 100 mg/kg BB of diethyl-nitrosamine intraperitoneal carcinogen for one distribution and 140 ppm of N-nitrosomorpholine intodrinking water in every day. Score assessment system of Metavir provides an indication of activity or the number of inflammation and is the number of fibrosis or scar tissue. The scores of fibrosis is also given the number ranging from 0 to 3 in which (0) no scar tissue, (3) Minimal scar tissue, (6) scar tissue occurred and spread outside of liver containing blood vessel, (9) Fibrosis spread and connecting to other area containing fibrosis and (12) Cirrhosis, (15), HCC. (10) The SD rats were fed with standard food of AD II with the composition




Figure 1. Profile of the tendency Arg-1, FN, IL-13, and TIMP-1, during the progression of liver fibrosis to occurs liver cirrhosis appear: A). Arg-1 serum showed a decline. B). serum FN-1 also showed a decline. C). serum IL-13 showed an increasing. D). serum TIMP-1 showed a increasing.

MATERIALS AND METHODS

This study was approved by Medical and Health Research Ethics Committee Faculty of Medicine GadjahMada University, Yogyakarta, Indonesia.

of maximum 12% of water, minimum 15% of unrefined protein, 3-7% of unrefined fat, maximum 6% of unrefined fibre, maximum 7% of ash, 0.9 to 1.1% of calcium, 0.6 – 0.9% of phosphor antibiotic, and coccidiostate. A histological examination was conducted in each 2 or 4 weeks to determine

the liver fibrosis, HCC, and to measure level of Arg-1, IL-13, FN, TIMP-1 in serum (Kilkenny *et al.*, 2010). Serum and liver tissue from 6 male Sprague-Dawley (SD) rats done sampling on each treatment group (4th, 8th, 10th, 12th, and 14th weeks). Two SD rats were used as the controller for each group in which all of rats had standard food of AD II. The serum was stored in each distribution 2 or 4 weeks in an -80°C. The measurement level of Arg-1 was done using the quantitative method of enzyme linked immunoassay (Qusabio, USA), and FN, IL-13, TIMP-1 using enzyme linked immunoassay (Booster, USA). Meanwhile, the staining of liver tissues by Haematoxylin Eosin and Malory Aniline Blue were performed for matrix extracellular. *Statistical methods:* The results were performed using statistical Program for Window Evaluation Version 15.0 (www.spss.com). Statistical analysis by univariate and multivariate analysis with models multiple regression used to assess liver fibrosis. Analysis indicator of progressivity fibrosis of the liver by Mann Whitney test, judging appearance, determination, and changes in blood chemistry and immunology to cirrhosis, and HCC.

RESULTS

The pattern of level of Arg-1, FN serum with mild fibrosis until cirrhosis, had diminishing correlation with profile of pathology anatomy, meanwhile the pattern of level of IL-13, and TIMP-1 serum the subject of rats from hepatitis and fibrosis to cirrhosis its opposite. (Figure 1.)

Cirrhosis refers to the presence of macro-nodular or in combination with the micro-nodular type. Whereas significant cellular changes to grow into dysplastic nodules (high or low levels) of hepatocellular carcinoma, after induction with DEN and N-Mor until week 14, the subjects of the mouse undergo a preneoplastic change (Ishak, 2000). After induced by DEN and N-Mor until the 14th week, the SD rats has been changed into preneoplastic rat. It was found that the levels of Arg-1 and FN at week 14th has changed significantly, Arg-1 ($p = 0.041$) and FN ($p = 0.002$), while the level of IL-13 and TIMP-1 was not changed to HCC. (Table 1, Figure2)

DISCUSSION

Liver cancer progresses in a large percentage of cases during the clinical course of chronic fibro-inflammatory liver diseases leading to cirrhosis. Therefore, HCC development is regarded as the result of different environmental risk factors each involving different genetic, epigenetic- and chromosomal alterations and gene mutations. During tumour progression, the malignant hepatocytes and the activated hepatic stellate cells are accompanied by cancer-associated fibroblasts, myofibroblasts (Berasain, 2009). In the past 10 years, a number of inflammatory mediators have been shown to contribute to the progression of chronic liver disease, 14, 15 many of which are either targets or activators of nuclear factor- κ B (NF- κ B). NF- κ B is a key transcriptional regulator of the inflammatory response, 16, 17 and plays an essential role in the regulation of inflammatory signaling pathways in the liver.




Figure 2. Association between liver fibrosis, schirrous HCC and Arg-1, FN, IL-13, TIMP-1 levels in serum.
A. Liver cirrhosis with severe fibrosis B. Dysplastic changes in hepatocytes cells (preneoplastic)

Table 1. Profile of seromarker ARG-1, FN, IL-13, TIMP-1 in liver cirrhosis transformed into HCC

	Cirrhosis	Scirrrosis with HCC	p
ARG-1	2.00±0.62	2.87±0.50	0.041
FN	614.44±57.44	1523.38±192.71	0.002
IL-13	83.60±29.04	92.91±29.04	0.483
TIMP-1	6247.92±216.54	6393.73±128.33	0.180

By multiregression analysis to see exponential trendline graph of Arg-1, FN, IL-13, TIMP-1 obtained respectively : $r = -0.870$ (95%CI:10.05-13.490), $r = -0.791$ (95%CI:9.27-13.73), $r = 0.932$ (95%CI:2.34-4.67), $r = 0.808$ (95%CI: -23.86- -6.61) $p = 0.000$ (Figure 1).

NF- κ B regulates multiple essential functions in hepatocytes, Kupffer cells and hepatic stellate cells (HSCs). Genetic inactivation of different NF κ B signaling components results in liver phenotypes that include spontaneous injury, fibrosis and carcinogenesis suggesting that NF- κ B makes an essential

contribution to liver homeostasis and wound-healing processes (Shiha, 2011; Inokuchi *et al.*, 2010; Bettermann *et al.*, 2010; Maeda *et al.*, 2005). NF- κ B inhibition by deletion of inhibitory κ B kinase -2 (IKK2) in hepatocytes resulted in increased liver tumor formation in the genotoxic diethylnitrosamine (DEN) tumor model (He *et al.*, 2010; Chrzanowska *et al.*, 2009). Arginase-1 (previously known as "arginase liver") is the core enzyme of the urea cycle and occurs in the periportal and hepatocyte. Besides urea, arginase participates in ornithine biosynthesis main compound for proline (for collagen), glutamate (for glutamine) and polyamine (for regulating the cell proliferation and regeneration). Involved in so many essential biochemical pathways, arginase might be the key point in the development of any pathological processes (Yan *et al.*, 2010). The immunohistochemical studies examining the expression of Arg-1 in a variety of neoplasms and normal tissue samples showed that the sensitivity and specificity of this marker for HCCs are 96.0% and 99.6%, respectively. In contrast, found that the sensitivity and specificity of HepPar-1 are 84.1% and 96.3%, respectively. It seems that the sensitivity of Arg-1 is consistently superior to that of HepPar-1 within each grade of HCC. The identification of Arg-1 as an immunohistochemical marker of hepatocellular neoplasms may lead to its development as a useful diagnostic adjunct in routine surgical pathology practice (Hart, 2010). This study found the level of seromarker Arg-1, its lowest in cirrhosis and increased markedly in HCC (Table 1).

Fibronectin produced by the tumor, endothelial, and Ito cells. Regarding their localization patterns in relation to the histological pattern of tumor, although present in the extracellular matrix of the subendothelial space sinusoid in each histologic pattern, the localization of these components in the intercellular spaces between tumor cells are most marked for hepatocellular carcinoma with solid (Reif *et al.*, 2003). In activated HSC downstream integrin signalling, via the focal adhesion kinase (FAK)-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway, promotes ECM deposition (Levental *et al.*, 2009). Increased ECM stiffness in vitro enhances integrin expression and activity and focal adhesion formation (Rybak *et al.*, 2007), with subsequent activation of downstream integrin signalling within the hepatocyte that may nurture the growth and survival of precancerous cells.

As shown in the research of Rybak *et al.* in 2007 the domain EDA fibronectin was characterized as the vascular marker that is neovascularisation in primer and metastases tumour (Moustafa *et al.*, 2012). In week 14th of this study with the induction of DEN and N-Mor, the level of FN increased due to the change in liver cell into preneoplastic (Table 1). The research of Moustafa *et al.* in 2012 compared the fibronectin plasma to the hepatitis fibrosis by 234.4 \pm 122 μ g/ml; while in HCC, the level of FN plasma increased by 322.6 \pm 80.57 μ g/ml (Deng *et al.*, 2015). Interleukin- (IL-) 13 is a cytokine secreted by several cell types, including eosinophils, mast cells, basophils, epithelial cells, smooth muscle cells, fibroblasts, macrophages, and T cells, especially Th2 cells. IL-13 participates in asthma, tumorigenesis, and parasitic diseases. In previous study, this performed a large case-control study that determined the association between SNP in the IL-13 gene and the presence of chronic hepatitis B and HBV-related HCC. The rs1800925 CT and TT genotypes were not associated with risk in either the chronic hepatitis B patients or the HBV-related HCC patients. Although the IL-13 rs20541 SNP does not appear to have a significant association with the risk of

chronic hepatitis B, we found a significant relationship between the rs20541 SNP and the risk of HCC (Deng *et al.*, 2015). The other study by Song *et al.* found that TIMP-1 is aberrantly up-regulated in 76.6% of HCC cells, which are associated with worse prognosis (Song *et al.*, 2015). Intriguingly, our findings of TIMP-1 expression in HCC samples are consistent with results from Lempinen's have significantly better overall survival than those with high concentrations group showing that HCC patients with low concentrations of serum TIMP-1 of serum TIMP-1. Thus, TIMP-1 merely functions as a biomarker for HCC progression and contributes to accelerating cancer progression, which implies that it may serve as an important HCC therapeutic target. The data in the study of Song *et al.* reveal that aberrant over expression of TIMP-1 in HCC cells initiate transformation from liver fibrosis (LFs) to carcinoma-associated fibroblasts CAFs (Song *et al.*, 2015). In this study showed levels of Arg-1 and FN seromarker, significantly associated with the development of liver fibrosis becomes HCC, contrary to seromarker IL-13 or TIMP-1. Meanwhile the previous studies by immunohistochemical liver tissue indicate Arg-1, FN, IL-13 and TIMP-1 have a relationship with the development of HCC. Conclusion: This finding suggests that determination of Arg-1, or FN serum are useful as an indicator for assess the progression of stromal fibrosis of cirrhosis become Scirrhus HCC.

Disclosure/conflict of interest:

The author declare no conflict of interest.

Acknowledgements

The author would like to acknowledge Prof. Dr sitinurdjanah, M.Kes, Sp PD, KGEH and Prof. dr Budi Mulyono, MM, Sp PK/K for their valuable contribution in conducting this research.

REFERENCES

- Mittal, S., and El-Serag, HB. 2013. Epidemiology of HCC: Consider the Population. *J Clin Gastroenterol.* 47(0):S2-S6
- Lin-Xiu Qin, Zhao-You Tang, 2002. The prognostic molecular markers in hepatocellular carcinoma, *World J Gastroenterol.* 8(3): 385-392
- El Fatah, WM., El-Kader, MR., Abdel-Hak, MT. 2016. Laminin and chromogranin A as serum markers of liver fibrosis in hepatocellular carcinoma. *Clin Med Diag.* 6(2):21-31.
- Wynn, TA. 2004. Fibrotic Disease and The TH1/TH2 Paradigm. *Immunology.* 4:583-594
- Yan, BC., Gong, C., Song, J., Krausz, T., Tretiakova, M., Hyjek, E., Al-Ahmadie, H., Alves, V., Xiao, SY., Anders, RA., Hart, JA. 2010. Arginase-1 Anew Immunohistochemical Marker of Hepatocytes and Hepatocellular Neoplasms. *Am J Surg Pathol.* 34(8):1147-1154
- Lichtinghagen, R., Bahr, MJ., Wehmeier, M., Michels, D., Haberkorn, CI., Arndt, B., *et al.* 2003. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C virus-induced liver cirrhosis. *Clin Sci.* 105:373-382

- Feng, Y., Cheung, KF., Wang, N., Liu, P., Nagamatsu, T., Tong, Y., *et al.* 2009. Chinese medicine as a resource for liver fibrosis treatment. *Chinese Medicine*. 4:1-16
- Pinzani, M., Rombouts, K., Colagrande, S. 2005. Fibrosis in chronic liver diseases: diagnosis and management. *J Hepatol*.45(Suppl.):S22–S36
- Chuang, SE., Cheng, AL., Lin, JK., Kuo, ML. 2000. Inhibition by Curcumin of Diethylnitrosamine - induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. *Food Chem Toxicol*.38(11):991-5.
- Shiha, G. and Zalata, K. (2011) Ishak versus METAVIR Terminology, Convertibility and Correlation with Laboratory Changes in Chronic Hepatitis C, *Liver Biopsy*, Dr Hirokazu Takahashi (Ed.) InTech, DOI:10.5772/20110. Available online at <http://www.intechopen.com/books/liver-biopsy/ishak-versus-metavir-terminology-convertibility-and-correlation-with-laboratory-changes-in-chronic-h>
- Kilkenny, C., Browne, WJ., Cuthill, IC., Emerson, M., Altman, DG. 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol*. 8: e1000412
- Ishak, KG. 2000. Pathologic Features of Chronic Hepatitis. *Am J Clin Pathol*, 113:40-55
- Berasain J, Castillo M J, Perugorria MU, Latasa J, Prieto and M A, Avila 2009. Inflammation and liver cancer: new molecular links. *Annals of the New York Academy of Sciences*. 1155: 206–221
- Bonacchi, A., Petrai, I., Defranco, RM., Lazzeri, E., Annunziato, F., Efsen, E., *et al.* 2003. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. *Gastroenterology*.125:1060–76.
- Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., *et al.* 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 β in mice. *Gastroenterology*.139:323–34
- Karin, M., and Ben-Neriah, Y. 2000. Phosphorylation meets ubiquitination: the control of NF- κ B activity. *Annu Rev Immunol*. 18:621–63.
- Xiao, C. and Ghosh, S. 2005. NF- κ B, an evolutionarily conserved mediator of immune and inflammatory responses. *Adv Exp Med Biol*.560:41–5
- Luedde, T., and Schwabe, RF. 2007. Deletion of NEMO/IKK γ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. *Cancer Cell*.11:119–32.
- Inokuchi, S., Aoyama, T., Miura, K., Osterreicher, CH., Kodama, Y., Miyai, K., *et al.* 2010. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. *Proc Natl Acad Sci U S A*.107:844–9.
- Bettermann, K., Vucur, M., Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., *et al.* 2010. TAK1 suppresses a NEMO-dependent but NF- κ B-independent pathway to liver cancer. *Cancer Cell*. 17:481–96
- Maeda, S., Kamata, H., Luo, JL., Leffert, H., Karin, M. 2005. IKK β couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. *Cell*. 121:977–990.
- He, G., Yu, GY., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., *et al.* 2010. Hepatocyte IKK β /NF- κ B inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. *Cancer Cell*.17:286–97.
- Chrzanowska, A., Gajewska, B., and Baranczy-Kuzma, A. 2009. Arginase isoenzymes in human cirrhotic liver. *Acta Biochim Pol*. 56(3): 465-69
- Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA. 2010. Arginase-1: A New Immunohistochemical Marker of Hepatocytes and Hepatocellular Neoplasms. *Am J Surg Pathol*.34(8): 1147–1154
- Tabarin A., Bioulac-Sage P., Boussarie L., Balabaud C., de Mascarel A., Grimaud JA. 1987. Hepatocellular carcinoma developed on noncirrhotic livers. Sinusoids in hepatocellular carcinoma. *Arch Pathol Lab Med*. 111(2):174-80
- Reif S, Lang A, Lindquist JN, Yata Y, Gäbele E, Scanga A, *et al.* 2003. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. *J Biol Chem*. 278:8083–90
- Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, *et al.* 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell*. 139:891–906
- Rybak J-N., Roesli C., Kaspar M., Villa A., and Neri D. 2007. The extra domain A of fibronectin is vascular marker of solid tumors and metastases. *Cancer Res*; 67(22): 10948-957
- Moustafa MM, El-Bawab El-S M, Moustafa HM, Mohamed IH, Salama M M, and Abd-Elzاهر MH 2012. Evaluation of Cystatin C, Fibronectin and Alpha-Feto Protein as Biochemical Markers in Patients with Liver Diseases. *J Am Sci*. 8(7):770-778
- Deng Y, Xie M, Xie L, Wang J, Li T, He Y, *et al.* (2015). Association between Polymorphism of the Interleukin-13 Gene and Susceptibility to Hepatocellular Carcinoma in the Chinese Population. *Plos One*. 10(2):e0116682 :1-10
- Song T, Dou, C, Jia, Y, Tu K, Xin Zheng X (2015). TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. *Oncotarget*. 6(14): : 12061-12079
